2013 saw much progress in breast cancer research. Advances in highthroughput technologies continue to refine our knowledge of the molecular biology of breast cancer, and are beginning to give insight into cancer evolution, drug resistance, and how to deploy precision therapeutics.
The tremendous molecular diversity in cancers, both between patients and within a single patient, challenges standard basic research techniques and traditional drug design and testing. Breast cancer is considered the most common cause of cancer deaths among women worldwide. It is a clinically and biologically heterogeneous disease that will require new approaches for the translation of precision medicine into new treatments tailored to the biology of the specific tumour.
In one comprehensive genomic report, The Cancer Genome Atlas (TCGA) researchers performed an analysis to identify somatic point mutations and small insertions or deletions in 12 cancer types. This study showed that breast cancer has one of the lowest mutation rates in solid tumours, with an average of ~3,000 somatic mutations per tumour (range ~90-60,000).
1 Breast cancers were enriched with mutations in TP53, PIK3CA, GATA3, MAP3K1, CDH1, and MLL3. In a separate study, Alexandrov and colleagues analysed somatic mutations from > 7,000 tumours (representing 30 different classes) and found that the mutation rate in breast cancer samples was strikingly similar to that observed in the TCGA pan-cancer analysis. 2 Breast cancers showed foci of h ypermutation-termed kataegis-that were associated with large structural rearrangements. Specific mutation signatures were strongly associated with tumours harbouring loss of BRCA1 or BRCA2. The researchers also identified a unique type of base pair mutation (C>T and C>G at TCN trinucleotides) that is consistent with aberrant activity of endogenous APOBECs proteins, cytidine deaminases that normally convert cytidine to uracil. Several other studies in 2013 revealed a role for the overexpression of APOBEC family members in breast and other cancers, suggest ing that the APOBEC-mediated cytidine deami nation might represent a general mechanism to generate mutations during tumorigenesis. Overall, published reports in the past 2-3 years have comprehensively identified several somatic point mutations and small insertions or d eletions in primary breast tumours.
Breast cancer genomics remains an evolving story, as most large sequencing studies have so far focused on primary breast cancer. Furthermore, recent reports of sequencing in metastases have described mutations that are absent or present at very low frequencies in primary tumours (such as in rare subclones), supporting the need for further mutational analysis of metastases. Indeed, one of the greatest surprises in breast cancer genetics in 2013 was the identification of mutations in the gene encoding the oestrogen receptor (ER, ESR1) in breast cancer metastases. As ER is a central driver and a primary target in breast cancer, most researchers had surmised that it must be mutated at least in some endocrine-resistant tumours. However, very few mutations have been identified despite intensive efforts. For example, TCGA identified somatic mutations in ESR1 in only two of 825 primary breast cancers (0.2%). The genomic landscape changed dramatically when the analysis was shifted from primary tumours to advanced-stage and hormone-resistant disease. In a Herculean effort designed to sequence and characterize patient-derived xenografts, Ellis and colleagues identified ESR1 somatic mutations in advanced-stage breast cancer samples from patients refractory to antihormonal therapy. 3 These findings were substantiated in two subsequent studies that reported the identification of ESR1 somatic mutations in six out of 11 (55%) and 14 of 80 (17.5%) patients with ER-positive metastatic breast cancer, respectively. 4, 5 Importantly, these mutations were found almost exclusively in advanced-stage ER-positive breast cancers, and they emerged after patients were treated with an aromatase inhibitor rather than an antioestrogen. The somatic mutations clustered in the ligand binding domain of the ER; structure-function studies showed that these mutations resulted in conformational changes to the ER, leading to its constitutive activation. This ligand-independent activity caused complete resistance to aromatase inhibitors and partial resistance to selective oestrogen-receptor modulators and degraders. Together, these findings open up a new avenue in the development of therapies for ER-positive advanced-stage breast cancer by investigating the mechanism of hormone action and suggest the use of inhibitors that specifically target the mutated ER.
Sequencing of distinct tumour regions, and single cancer cells, has revealed tremendous intratumour heterogeneity. TCGA and other large genomic projects have struggled to address the degree of intratumour hetero geneity. Moreover, determining the extent and clinical significance of such hetero geneity is hampered by the difficulty in obtaining repeated tissue biop sies. An attractive alternative is the NPG www.nature.com/nrclinonc YEAR IN REVIEW exami nation of circulating cancer DNA in plasma (circulating-free DNA or cfDNA), the so-called liquid biopsy. The year 2013 saw two reports on longitudinal analysis of whole-exome and whole-genome sequencing of cfDNA in patients with breast cancer. Whole-exome sequencing of cfDNA collected over 1-2 years from patients with advanced-stage breast cancer showed that mutations detected in liquid biopsies arose or increased in frequency in conjunction with the development of clinical therapeutic resistance. 6 In one patient, treatment with tamoxifen and trastuzumab (an anti-HER2 monoclonal antibody) was followed by an increase in the truncation of MED1 (mediator complex subunit 1) gene product, an ER co-activator known to be involved in tamoxifen resistance. Subsequent treatment of this patient with lapatinib and capecitabine was followed by an increase in a splicing mutation in GAS6, encoding the ligand for tyrosine kinase receptor AXL, which has been shown to cause resistance to lapatinib. 6 Moreover, Dawson et al. 7 describe the use of whole-exome and whole-genome sequencing of cfDNA to design patient-specific assays for longitudinal monitoring. cfDNA was detected in 29 out of 30 (97%) patients with advanced-stage breast cancer, whereas elevated levels of CA15-3 antigen and circulating tumour cells were only detected in 78% and 87% of the patients, respectively. Importantly, an increase in cfDNA was detected months before confirmation of disease progression by CT scan. These studies highlight the potential of using cfDNA to monitor disease burden and progression, and also the ability to identify possible targets to treat the disease and prevent the emergence of drug resistance.
The use of massively parallel sequencing to personalize genomic-directed breast cancer therapy is becoming a reality.
However, the number of approved 'targeted' drugs remains low, and the path for their clinical development and testing is unacceptably long. A fast-track path for approval of new therapeutics is needed to tackle the diverse array of somatic mutations found in breast cancer. In May 2012, the FDA provided guidelines for the use of pathological complete res ponse (pCR) as an end point to support the develop ment and accelerated approval of new agents in the setting of neoadjuvant treatment of high-risk early stage breast cancer. In 2013, pertuzumab (Genentech, USA) was the first agent to benefit from the new guidance and received approval as a neo adjuvant treatment for patients with HER2-positive early stage breast cancer. Finally, in 2013, the results of four large clinical trials designed to optimize the use of active targeted agents were reported. The ATLAS trial compared 10 years versus 5 years of tamoxifen treatment in 12,894 women with early stage breast cancer, 8 and concluded that continuing tamoxifen to 10 years rather than stopping at 5 years produced a further reduction in recurrence and mortality. The greatest effect of extended tamoxifen treatment was observed from year 10 to year 15, with a recurrence rate ratio of 0.75 and a mortality rate ratio of 0.71. These data were confirmed by the preliminary results of the aTTom trial. How ever, although these findings-combined with previous reports of extended aromatase inhibitor use after tamoxifen-highlight the value of extended adjuvant hormone treatment, this model does not hold true for all adjuvant therapies. Indeed, the PHARE trial showed that 6 months of adjuvant trastuzumab cannot be regarded as a substitute for the current stand ard treatment of 1 year of trastuzumab. 9 The HERA trial results demonstrated that 2 years of adjuvant trastu zumab treatment was not more beneficial in reducing recurrence of HER2-positive breast cancer than 1 year of treatment. 10 The differ ence between optimal length of adjuvant tamoxifen and trastuzumab therapy could have several explanations, but one might be the relative indolence of ER-positive dis ease in which endocrine therapies, such as tamo xifen, act to control the dormancy of micro metastases. These findings suggest that targeted t herapies will require extensive optimization.
We foresee that the coming years will continue to improve our knowledge of breast cancer. New techniques that include deep sequenc ing and digital multiplexed patho logy are enabling unprecedented investigations into the underpinnings of breast cancer that will likely have a major impact on t reatment and prevention.
